(312/759): ALGRX 4975 reduces pain of acute lateral epicondylitis: Preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial

Abstract

ALGRX 4975 is capsaicin for injection. Subjects with lateral epicondylitis of less than three months duration received a single injection of ALGRX 4975, 100 μg in 0.5 ml, or placebo, 0.5 ml, at the site of maximum tenderness 10 minutes following lidocaine, 250 mg in 2.5 ml. The primary efficacy endpoint was pain on resisted wrist dorsiflexion, defined as 0= no pain on resisted dorsiflexion, 1= full range of motion with slight pain, 2= moderate, and 3= marked pain on dorsiflexion, and 4= dorsiflexion not possible due to pain.